Cystic Fibrosis Lung Disease in the Aging Population

Abstract

The demographics of the population with cystic fibrosis (CF) is continuously changing, with nowadays adults outnumbering children and a median predicted survival of over 40 years. This leads to the challenge of treating an aging CF population, while previous research has largely focused on pediatric and adolescent patients. Chronic inflammation is not only a hallmark of CF lung disease, but also of the aging process. However, very little is known about the effects of an accelerated aging pathology in CF lungs. Several chronic lung disease pathologies show signs of chronic inflammation with accelerated aging, also termed “inflammaging”; the most notable being chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). In these disease entities, accelerated aging has been implicated in the pathogenesis via interference with tissue repair mechanisms, alterations of the immune system leading to impaired defense against pulmonary infections and induction of a chronic pro-inflammatory state. In addition, CF lungs have been shown to exhibit increased expression of senescence markers. Sustained airway inflammation also leads to the degradation and increased turnover of cystic fibrosis transmembrane regulator (CFTR). This further reduces CFTR function and may prevent the novel CFTR modulator therapies from developing their full efficacy. Therefore, novel therapies targeting aging processes in CF lungs could be promising. This review summarizes the current research on CF in an aging population focusing on accelerated aging in the context of chronic airway inflammation and therapy implications.

Introduction

30 years ago, mutations in the cystic fibrosis transmembrane regulator (CFTR) gene were characterized as single gene defect leading to the pathology of cystic fibrosis (CF) (Kerem et al., 1989; Tsui, 1995). Since then, our understanding of the pathological processes has largely improved with CFTR targeted modulator therapies in clinical use (Wainwright et al., 2015; Rowe et al., 2017; Taylor-Cousar et al., 2017; Davies et al., 2018; Keating et al., 2018). Nevertheless, progressive lung disease is still the major cause for morbidity and mortality in individuals born with CF (Elborn, 2016). Functional failure of CFTR results in impaired ciliary function, mucus obstruction, bacterial colonization and chronic inflammation (Matsui et al., 1998; Mall et al., 2004; Boucher, 2007). This sets the stage for smoldering chronic infections interrupted by episodic exacerbations due to newly acquired pathogens leading to progressive loss of lung function (Nichols et al., 2008; Elborn, 2016). Elevated levels of pro-inflammatory mediators, reactive oxygen species (ROS), and proteases, which further propagate airway inflammation, can accelerate cellular senescence (Bezzerri et al., 2019).

Major improvements in supportive therapies and the development of CFTR targeted therapies increased life expectancy in CF patients to a median survival of 40 years or more in industrialized nations (Dodge et al., 2007; MacKenzie et al., 2014). Hence, CF is no longer considered primarily a pediatric disease. This entails new challenges, including treatment of CF in an aging population with CF dependent and independent comorbidities. Diabetes, osteopenia and osteoporosis, renal, and vestibulocholear complications from aminoglycoside toxicity, cardiovascular disease, and worsening lung disease are medical issues often emerging in the aging CF population (Hodson et al., 2008; Simmonds et al., 2009). Chronic local and systemic inflammation is a key pathogenic mechanisms suspected of promoting these comorbidities (Nichols et al., 2008; Bezzerri et al., 2019). Aging impairs lung function through several mechanisms, a central being chronic, low-grade inflammation termed “inflammaging” (Franceschi and Campisi, 2014). Accelerated aging has been implicated in several chronic inflammatory lung disease pathologies. As chronic inflammation is a hallmark of CF airway disease, the question arises whether this chronic inflammation may also cause premature aging in CF lung tissue; and if so whether novel therapies targeting “inflammaging” and aging pathomechanisms in CF lungs might prove to be beneficial.

Hallmarks of Aging in CF Lung Disease

Physiological aging is associated with considerable changes in lung structure and cell function, giving rise to reduced lung function, pulmonary remodeling, diminished regenerative capacity, and enhanced susceptibility to lung injury, and disease (Cho and Stout-Delgado, 2020). Considering the increased life expectancy of CF patients, the question whether chronic inflammation contributes to accelerated aging becomes more and more relevant. Interestingly, healthy aging lungs show a proinflammatory state with increased neutrophils and IL-8 (Meyer et al., 1998), bearing some similarity with chronic CF lung inflammation. In the following paragraphs we aim to provide an overview on the hallmarks of aging and their potential implications for CF lung disease. Central findings on accelerated aging in CF are also summarized in Figure 1.

FIGURE 1

Genomic Instability

Non-transplanted CF patients have a higher risk for lymphoid leukemia, testicular cancer and digestive tract cancers than the general population (Maisonneuve et al., 2013). Similarly, cancer risk in CF lung transplant recipients is more increased than in non-CF recipients, particularly for colorectal cancer, esophageal cancer, and non-Hodgkin lymphoma (Fink et al., 2017). Defects in CFTR themselves have been linked to cancers (Scott et al., 2020). The striking overlap of organ systems with elevated cancer risk and those that are primarily affected by CF-associated mucus hypersecretion, i.e., the respiratory, digestive, and reproductive systems, strongly implicates chronic inflammation as a potential causative factor. In CF airway inflammation, large numbers of activated neutrophils release reactive oxygen species (ROS) and proteases, such as neutrophil elastase, thereby inducing additional ROS production in lung cells (Brown and Kelly, 1994; Aoshiba et al., 2001). In addition, reduced antioxidant defense with systemic glutathione deficiency, reduced vitamin E plasma levels, and increased mitochondrial oxidative stress has been reported in CF patients (Roum et al., 1985; Brown et al., 1995; Starosta et al., 2006; Velsor et al., 2006). Not surprisingly, CF lungs are exposed to significantly higher oxidative stress levels (Starosta et al., 2006). As marker of oxidant-induced DNA damage, urinary 8-hydroxydeoxyguanosine (8-OHdG) was found to be significantly elevated in children with CF (Brown and Kelly, 1994). Further, airway epithelia from CF patients show increased expression of two DNA damage markers (phospho-Histone H2A.X (γH2A.X) and phospho-checkpoint 2 kinase (phospho-Chk2)) (Fischer et al., 2013). However, it would be too simplistic to attribute the increased cancer risk solely to oxidative stress. CFTR has been proposed a tumor suppressor protein and CFTR deficiency is implicated in airway and intestinal cancer progression and poor prognosis (Than et al., 2016; Li et al., 2015; Tu et al., 2016). In summary, aging-associated DNA repair deficiency in combination with increased oxidative damage can lead to accumulating genome damage and thus to genomic instability (Moskalev et al., 2013).

Telomere Attrition

The proliferative capacity of cells is limited by the gradual loss of their protective telomeric DNA with each division ultimately leading to cellular senescence (Blackburn et al., 2006). Chronic inflammation can not only increase cell turnover, it has also been shown to lead to telomere dysfunction and accelerated aging (Jurk et al., 2014; Gorenjak et al., 2020). Telomeres are highly sensitive to oxidative damage as it is ineffectively repaired causing accelerated telomere loss (Gorenjak et al., 2020; Hewitt et al., 2012). This raises the question whether oxidative stress associated with chronic airway inflammation can cause accelerated telomere shortening in CF patients.

In CF, decreased telomere length in peripheral blood leukocytes has been reported to be associated with disease severity (Lammertyn et al., 2017). However, telomere length was not reduced in explant lungs from CF patients, and no correlation between telomere length and disease severity at the sampling location was found (Everaerts et al., 2018). Similarly, telomere length in CF airway epithelial cells was not significantly different from control donor lungs; only a small subgroup of CF subjects had shorter telomeres (Fischer et al., 2013). Based on the limited scientific data available, we cannot conclude whether telomere attrition is a common feature in CF lungs. Further research is needed to determine its contribution to CF airway disease pathogenesis.

Epigenetic Alterations

Epigenetic alterations are stable, heritable changes to the chemical DNA structure by alterations in its methylation pattern, post-translational histone modifications, and chromatin remodeling. They regulate gene expression without modifying the DNA sequence (Gonzalo, 1985; Berger et al., 2009). Specific changes in the histone modification pattern such as increased H4K20 and H3K4 trimethylation, and decreased H3K9 methylation as well as H3K27 trimethylation constitute markers of age-associated epigenetic alterations (Gonzalo, 1985; López-Otín et al., 2013). DNA methylation has been shown to play an important role in aging and disease. Global DNA methylation changes over the lifespan and methylation of specific CpG (cytosine guanine) sites correlate with age (Jones et al., 2015; Ashapkin et al., 2017; Levine et al., 2018). Alterations in DNA methylation patterns are associated with cancer, several genetic diseases and inflammatory lung conditions including CF (Robertson, 2005; Scott and De Sario, 2020). In CF, methylation changes were found at multiple CpG dinucleotides in nasal epithelial cells, whole blood and lung macrophages. Interestingly, these epigenetic alterations were preferentially located at genes important for the respective tissue, such as for cell adhesion, immune response or inflammation, and correlated with lung function (Scott and De Sario, 2020; Magalhães et al., 2018; Chen et al., 2018). Though the specific research is yet in its infancy, CFTR has been shown to be epigenetically regulated too which may open up novel therapeutic strategies to restore CFTR dysfunction in CF pathology (Sirinupong and Yang, 2015).

Loss of Proteostasis

Molecular chaperones and the proteolytic machinery assure continuous proteome renewal protecting cells from accumulation of misfolded or damaged proteins (López-Otín et al., 2013). Loss of adequate proteostasis occurs during the aging process and has been shown to be altered in CF epithelia. There is increasing evidence that CFTR function can regulate the proteostasis network (Villella et al., 2013; Esposito et al., 2016). CFTR carrying the ∆F508 mutation as well as other less frequent mutations does not mature into the fully glycosylated protein. Instead, the misfolded protein is mostly retained at the endoplasmic reticulum, where it is sequestered for degradation (Cheng et al., 1990; Van Goor et al., 2011). ∆F508 overexpression causes ER stress and activates the unfolded protein response in vitro leading to decreased wild type CFTR mRNA levels (Bartoszewski et al., 2008). This implicates defective CFTR leads to suppressed CFTR expression. The severity of the clinical disease spectrum varies considerably even within patients carrying the same mutation. Variations in the proteostasis network are suspected to be modifying factors contributing to those differences (Balch et al., 2011). A promising new therapeutic strategy aims at improving protein trafficking by the proteostasis network (Strub and McCray Jr, 2020). The proteostasis regulator cystamine promotes ∆F508-CFTR trafficking to the apical cell membrane and thereby allows it to respond to CFTR potentiators (Luciani et al., 2012). Cystamine combined with epigallocatechin gallate restored CFTR function, reduced lung inflammation and restored autophagy in a phase-2 trial, particularly in patients carrying the ∆F508 mutation (Tosco et al., 2016).

CFTR is not only subjected to degradation by the proteostasis network, it is a key player in its own regulation. Inhibition of CFTR function leads to CFTR protein ubiquitination and drastically reduced stability in the plasma membrane of bronchial epithelial cells (Esposito et al., 2016), with cystamine correcting this deranged proteostasis (Villella et al., 2013). In addition, siRNA depleting CFTR interferes with endosomal trafficking of cell surface proteins demonstrated for transferrin receptor, epidermal growth factor receptor, and CFTR itself (Villella et al., 2013). Hence, insufficient CFTR function derails the proteostasis network in a feed-forward loop fostering its own degradation. Dysfunctional autophagy also appears to contribute to the exaggerated CF lung inflammation. Improving autophagosome clearance attenuates the hyperinflammatory response (Mayer et al., 2013). Oxidative stress from defective CFTR function inhibits ubiquitination and proteasome degradation of the pro-fibrotic tissue trans-glutaminase 2, thereby driving chronic inflammation (Esposito et al., 2016; Luciani et al., 2009). Autophagy restoration by cystamine has been shown to suppress trans-glutaminase 2 and diminish inflammation in CF mice and in patient derived nasal epithelial cells in vitro. In summary, loss of proteostasis as an aging hallmark in CF disease has been established by current evidence and might be a valuable target for future therapies.

Deregulated Nutrient Sensing

Aging is regulated by nutrient-sensing pathways including insulin/insulin-like growth factor (IGF-1), mTOR, AMP kinase, sirtuins, and FOXO transcription factors (Vellai, 2009; Kenyon, 2010). Pro-inflammatory signals are closely integrated in stress and nutrient signaling (Jurk et al., 2014). Hence, both inflammaging and chronic inflammatory conditions such as CF lung disease have the potential to interfere with nutrient sensing signaling pathways. An in vitro study identified the α1 (catalytic) subunit of AMP-activated protein kinase (AMPK) as a dominant and novel protein interacting with CFTR demonstrating a potential link between transepithelial transport and cell metabolic state (Hallows et al., 2000).

Oxidative stress as seen in CF airway inflammation leads to increased pro-growth signaling by the mTOR pathway (Chen et al., 2011). So far, only little is known about deregulated nutrient sensing in CF lung disease. CFTR has been found to interact with mTOR signaling pathway components, which can be affected by CFTR mutations such that ∆F508 CFTR exhibits a specific interactome different from wild type CFTR (Pankow et al., 2015; Reilly et al., 2017). mTOR activity in CF bronchial epithelial cells is upregulated, and PI3K/Akt/mTOR pathway inhibition improves CFTR expression and stability (Reilly et al., 2017). FOXO transcription factors down stream of insulin/IGF-1 signaling (IIS) regulate cellular processes involved in stress resistance, metabolism as well as cell cycle arrest, and are central to IIS attenuation-mediated lifespan expansion (Martins et al., 2016). FOXO1 and 3 have been shown to regulate innate immune mechanisms in respiratory epithelia in response to bacterial infections (Seiler et al., 2013). In a human CF bronchial epithelial cell line, reduced FOXO1 was found related to loss of CFTR function (Smerieri et al., 2014). Interestingly, four miRNAs that are predicted FOXO1 regulators were differently expressed in CF patient sera (Montanini et al., 2016). However, the implications of altered FOXO transcription factor signaling in terms of accelerated aging in CF patients remains unclear and calls for further investigation.

Mitochondrial Dysfunction

Age-associated mitochondrial dysfunction is most commonly caused by increased ROS ultimately leading to cell senescence (Chapman et al., 2019). Excessive oxidant levels from dysfunctional mitochondria can trigger inflammatory cytokine release inducing chronic inflammation and progression of airway diseases such as CF (Prakash et al., 2017). In addition, as cells age, DNA damage occurs and activates DNA damage response pathways. These chronically stimulated pathways cause mitochondrial stress leading to increased release of mitochondrial damage-associated molecular patterns (DAMPs). DAMPs along with ROS production, and/or ATP and K⁺ efflux contribute to NLRP3 inflammasome activation (Prakash et al., 2017; dos Santos et al., 2012). This leads to caspase-1 activation and release of the proinflammatory cytokines IL-1β and IL-18, initiating a cycle of chronic inflammation, disease progression, and further accumulative damage to mitochondria resulting in accelerated aging (dos Santos et al., 2012). Recent research is showing that mitochondrial dysfunction could be involved in disease progression in CF. Cells with impaired CFTR function exhibit reduced mitochondrial complex I activity (Valdivieso et al., 2012). And increased IL-1β levels are very common among CF patients, which has been linked to inflammation triggered by underlying chronic Pseudomonas aeruginosa infections (Rimessi et al., 2015). As discussed, elevated IL-1β is not only a sign of inflammation, but also a hallmark of mitochondrial dysfunction. These two intrinsically connected hallmarks of aging both contribute to disease progression in CF. Furthermore, it will be of benefit to assess whether the triple CFTR modulator therapy affects these pathogenetic mechanisms favorably. A recent study has shown that CFTR modulation can restore Nrf2 phosphorylation, a major regulator of oxidative balance and inflammatory signaling (Borcherding et al., 2019).

Cellular Senescence

Accumulation of senescent cells is seen in normal aging and chronic pulmonary disease (Jeyapalan et al., 2007; Meiners et al., 2015). Senescence is triggered by a range of insults such as oxidative stress, DNA damage, telomere shortening, and inflammation, and is associated with a characteristic secretory profile termed senescence-associated secretory phenotype (SASP) (Naylor et al., 2013; Jurk et al., 2014). This includes release of proinflammatory mediators, growth factors, and matrix-remodeling proteases that may perpetuate inflammatory processes resulting in further accumulation of senescent cells (Naylor et al., 2013; Parikh et al., 2019). In CF, the liquid lung lining layer contains high amounts of neutrophil elastase that has been shown to trigger cell cycle arrest through elevated p27^Kip1 expression resulting in G1 arrest in normal human bronchial epithelial cells in vitro (Nakamura et al., 1992; Fischer et al., 2007). Cell cycle arrest may lead to cellular senescence (Fischer et al., 2013; Naylor et al., 2013). Indeed, a study by Fischer and colleagues confirmed airway epithelia from CF lungs have increased expression of the senescence markers p16^INK4a, γH2A.X, and phospho-Chk2 (Fischer et al., 2013). Their study showed that neutrophil elastase increases p16 expression resulting in inhibition of cyclin-dependent kinase 4 activity in vitro (Fischer et al., 2007). This suggests cellular senescence due to excessive neutrophil elastase release in CF lungs may contribute to accelerated aging. A recent review concluded there was consistent data supporting that cellular senescence may also be involved in CF lung disease, but the exact mechanisms leading from loss of CFTR function to cellular senescence and the precise role in CF lung disease remain unknown (Bezzerri et al., 2019).

Stem Cell Exhaustion

Lung tissue has a low steady-state cell turnover with the ability to increase proliferation of stem/progenitor cells in response to injury (Hogan et al., 2014). Aging is associated with a progressive decline of stem/progenitor cells that maintain homeostatic and regenerative capacity (Oh et al., 2014). Chronic inflammation is considered a main factor accelerating the deterioration of stem cell function with transforming growth factor (TGF)-β and ROS accumulation as important pathological factors (Oh et al., 2014). miRNA-155 is upregulated in aging and has been suggested to contribute to inflammation-associated stem cell dysfunction (Teramura and Onodera, 2018). High expression of this specific miRNA has been found in CF lung epithelial cells and circulating neutrophils (Bhattacharyya et al., 2011). Further, chronic airway inflammation in combination with recurrent exacerbations causes recurrent tissue damage thereby increasing the need for stem cell proliferation. This may exceed the supply the stem cell niche is capable of providing resulting in its depletion in CF lungs (Mora and Rojas, 2013). To this point, there are no reports on the exact role of stem cell exhaustion in CF lung disease. One study observed no telomere shortening in CF airway epithelial cells leading to the conclusion that the epithelial stem/progenitor reserve is sufficient to maintain normal telomere length despite enhanced cell turnover (Fischer et al., 2013). But this does not exclude an involvement of stem cell exhaustion in accelerated aging in CF lungs, and further studies are needed to draw definite conclusions.

Altered Cellular Communication

In addition to chronic lung inflammation, CFTR deficiency has been reported to causes abnormalities in diverse signaling pathways. Functional CFTR has been reported to downregulate NF-κB activity and CF associated hyper-inflammation may represent a consequence of insufficient inhibition of NF-κB signaling (Hunter et al., 2010). Chronic, progressive low-grade inflammation promoted by NF-κB can cause premature aging (Jurk et al., 2014). CF airway inflammation is associated with excessive production of NF-κB- dependent inflammatory mediators such as interleukin-1β (IL-1β), IL-6, IL-8, and TGF-β1, neutrophil recruitment, and decreased response to interferon (IFN)-γ as well as further abnormalities in various signaling pathways (Nichols et al., 2008; Harris et al., 2009; Peterson-Carmichael et al., 2009; Lara-Reyna et al., 2020). The profibrotic cytokine TGF-β is considered a pro-aging factor and is associated with accelerated lung function decline in CF patients (Arkwright et al., 2000). Several reports show that TGF-β causes CFTR dysfunction (Manzanares et al., 2015; Snodgrass et al., 2013; Sun et al., 2014). Chronic bacterial infections stimulate persistent IL-8 release from airway epithelia (McCuaig and Martin, 2013). Attracted neutrophils further potentiate airway inflammation by releasing high concentrations of inflammatory mediators such as TNFα and IL-8, oxidants, and proteases (Petit-Bertron et al., 2008). Neutrophil elastase promotes CFTR degradation and dysfunction by calpains (Le Gars et al., 2013). Recent drug developments have focused on restoring CFTR function; these therapies significantly improve lung function and reduce exacerbations in CF patients (Wainwright et al., 2015; Rowe et al., 2017; Davies et al., 2018; Keating et al., 2018). However, sustained airway inflammation leads to degradation and increased turnover of CFTR, hindering the targeted therapies from developing their full potential by inducing a state of accelerated aging at the tissue level (Rowe et al., 2014). Oxidative stress from ROS associated with neutrophilic airway inflammation can lead to accumulation of modified or damaged biomolecules impairing their function. Oxidatively damaged cellular structures can act as DAMPs that are recognized by receptors of the innate immune system, i.e., Toll-like-receptors (TLRs) and the NLRP3 inflammasome (Meiners et al., 2015). Hence, oxidative stress can further enhance cytokine production in the ongoing inflammation and maintain the proinflammatory state in inflammaging (Franceschi and Campisi, 2014; Meiners et al., 2015).

Extracellular Matrix Dysregulation

ECM remodeling in lung diseases is not only a consequence of tissue injury, it also contributes to disease progression by impaired repair mechanisms (Parker et al., 2014). The neutrophilic inflammation in CF is accompanied by protease/antiprotease imbalance with increased neutrophil elastase and matrix metalloprotease-9 and reduced tissue inhibitor of metalloprotease-1 (Gaggar et al., 2007). While proteolytic enzymes are beneficial for tissue repair, excessive release due to chronic inflammation may overwhelm anti-protease activity causing airway remodeling and obstruction (Gaggar et al., 2011). Neutrophil derived proteases are the main driving force of lung injury in CF (Elborn, 2016) and sputum neutrophil elastase correlates with FEV₁ in children with CF (Sagel et al., 2002). Furthermore, neutrophil elastase and proteolytic collagen and elastin breakdown products play a pathogenic role in fibrotic lung remodeling (Chua and Laurent, 2006). Ultrastructural evidence for ECM degradation includes lysis of elastic and collagen fibers, loss of arborescent elastic network distribution and alterations in the reticular basement membrane structure (RBM) (Durieu et al., 1998; Hilliard et al., 2007; Regamey et al., 2011). In CF, RBM thickening appears to be related to increased TGF-β1 levels (Hilliard et al., 2007). The elastic network reduction combined with increased collagen deposition in bronchial walls of CF patients resembles fibrotic ECM changes in aging lungs (Hilliard et al., 2007). Together, these data suggest that ECM dysregulation plays an important role in accelerated lung aging in CF.

Therapeutic Implications

Current Effective CF Therapies Targeting Chronic Inflammation

Various drugs targeting inflammation have been studied in CF since 1990, but only few are recommended for clinical use. Due to the length of this review, only significant ones will be discussed here.

Corticosteroids were one of the first anti-inflammatory drugs studied as a chronic therapy attenuating CF airway inflammation (Auerbach et al., 1985; Eigen et al., 1995). Although beneficial effects on lung function were shown, overall adverse effects outweighed the benefits and long-term use of systemic corticosteroids to slow lung function decline is currently not recommended (Flume et al., 2007). Several studies investigated the effects of inhaled corticosteroids (ICS) on lung function decline, but their anti-inflammatory effect was never confirmed (Ren et al., 2008; De Boeck et al., 2011). The CF Foundation therefore is advising against the use of long-term ICS in patients with CF older than 6 years without coexistent asthma or allergic bronchopulmonary aspergillosis (Flume et al., 2007).

Nonsteroidal anti-inflammatory drugs (NSAIDs) have been studied as therapeutic options for CF due to similar properties as corticosteroids, but fewer adverse effects. Ibuprofen has specific activity against neutrophils and twice-daily high-dose ibuprofen use was linked to a slower lung function decline, a decreased exacerbation frequency and less weight loss in the pediatric CF population (Konstan et al., 1995; Konstan et al., 2003; Konstan et al., 2007; Lands et al., 2007). Nevertheless, ibuprofen is not widely used, but the CF Foundation expert panel recommends its use for CF patients with mild lung disease (Flume et al., 2007).

CFTR modulator therapy has demonstrated its efficacy and beneficial effect on restoration of CFTR function for approximately 90% CF genotypes (Wainwright et al., 2015; Rowe et al., 2017; Davies et al., 2018; Keating et al., 2018; Middleton et al., 2019). Interestingly, CFTR dysfunction has been linked to contribute to chronic inflammation as well as other hallmarks of aging, and two recent studies have demonstrated an anti-inflammatory effect of CFTR modulators (Jarosz-Griffiths et al., 2020; Hisert et al., 2017). A recent observational study though did not show any significant alterations in sputum inflammatory markers, but changes in ECM using whole proteome analysis (Kopp et al., 2020). Therefore, the validation of potential anti-inflammatory effects of CFTR correctors needs further investigation. CFTR correctors also have been shown to act as proteostasis regulators (Lopes-Pacheco et al., 2015; Lopes-Pacheco et al., 2016) and there is evidence that CFTR modulators can regulate mitochondrial dysfunction. Figure 2 summarizes current evidence of CFTR modulators and their link to aging hallmarks.

FIGURE 2

Potential Novel CF Therapies

Modulation of ion channels other than CFTR has been evaluated as potential therapies. Most recently, potentiation of TMEM16A using ETX001 significantly increased the Ca²⁺-activated Cl⁻ channel activity and anion secretion both in vitro and in vivo ovine models leading to improved mucociliary clearance without impacting calcium signaling (Danahay et al., 2020). Whether ETX001 also affects airway inflammation will be of great interest.

Anti-inflammatory cytokines and antibodies targeting cytokines may be valuable novel CF therapies. IL-10 has been demonstrated to terminate the inflammatory response and is deficient in CF patients (Bonfield et al., 1999). And its administration is anti-inflammatory in Pseudomonas infected mice (Chmiel et al., 1999; Soltys et al., 2002). Treatment with the anti-inflammatory cytokine IFN-γ was tested in a multicenter clinical trial but did not show any beneficial effect on pulmonary function or inflammatory sputum markers (Moss et al., 2005). This is in line with the above-mentioned reduced response of CF airways to IFN-γ. As an alternative to the treatment with anti-inflammatory cytokines, various blocking antibodies targeting pro-inflammatory cytokines have been assessed. Anti-IL-17 antibodies have been shown to decrease neutrophil recruitment in murine airways when exposed to lipopolysaccharide (Ferretti et al., 2003). Anti-IL-17 has been tested clinically in rheumatoid arthritis and psoriasis (Ly et al., 2019; Taams, 2020) and might be a potential novel therapeutic strategy for CF-associated airway inflammation. Anti-ICAM-1 and -IL-8 have been assessed preclinically, but never reached the clinical stage. Because of high concentrations of LTB₄ in CF airways (Konstan et al., 1993) BIIL 284 BS (amelubant), a specific LTB₄ receptor antagonist, has been tested in CF. Due to serious pulmonary adverse events, the clinical trial was terminated early (Konstan MW et al., 2005).

Fatty acid modulation may proof beneficial as alterations in fatty acid concentrations contributing to airway inflammation have been demonstrated in CF such as increases in arachidonic acid and decreases in docosahexaenoic acid (DHA) (Freedman et al., 1999; Horati et al., 2020). Cumulative data from in vitro studies and some small, non-placebo controlled trials using oral DHA supplementation imply this may be beneficial for pulmonary function preservation (Beharry et al., 2007; Van Biervliet et al., 2008; Aldámiz-Echevarría et al., 2009). To validate these results, larger placebo-controlled trials will be needed. Furthermore, Myriocin, an inhibitor of sphingolipid synthesis, induced changes in a transcriptional program of cell metabolism in vitro in CF airway epithelial cells. Therefore, the authors speculated that sphingolipid de novo synthesis could attenuate chronic inflammation, optimize energy supply, and anti-oxidant responses, implying a novel future therapeutic strategy for CF (Mingione et al., 2020)

Inhibiton of NF-κB activation has been demonstrated by both ibuprofen at high doses and IL-10. Furthermore, NF-κB signaling can be attenuated by glitazones through peroxisome proliferator activating receptor (PPAR) elevation (Zingarelli et al., 2003; Ruan et al., 2003) and there seems to be a deficiency of PPAR in CF (Perez et al., 2008). Both tiglitazone and troglitazone can activate PPAR in the CF epithelium and attenuate the inflammatory response to P. aeruginosa (Perez et al., 2008). One clinical trial using glitazones has not shown a beneficial effect towards inflammation, but this trial was very small and did not assess lung function outcomes (Konstan MW et al., 2009). Long term use of Azithromycin has not only been shown to improve functional outcomes, but some of the underlying mechanisms can be attributed to STAT and NF-κB inhibition (Haydar et al., 2019; Nichols et al., 2020). In summary, targeting NF-κB signaling in CF disease seems to be an attractive future therapeutic direction.

Inhibition of the NLRP3 Inflammasome has also been discussed as a potential anti-inflammatory strategy (Scambler et al., 2019). A recent report utilized MCC950 as a specific NLRP3 inhibitor in vivo in CF animal models, which resulted in significantly reduced airway inflammation and improved Pseudomonas clearance (McElvaney et al., 2019).

Statins exhibit anti-inflammatory effects through various mechanisms including inhibition of neutrophil migration, RhoGTPase/increase in nitric oxide (NO)/IL-8 production and other proinflammatory cytokines as well as increase of PPAR transcription (Dunzendorfer et al., 1997; Kraynack et al., 2002; Zelvyte et al., 2002). Agents that can increase NO, such as arginine, have been studied, since it has been shown that there is increased arginase activity in blood and sputum of CF patients. This leads to degradation of L-arginine, which is a substrate for NO production (Grasemann et al., 2005a). A small pilot study assessed oral supplementation with L-arginine in CF patients, which led to increased exhaled NO (Grasemann et al., 2005b). In order to show efficacy, large prospective clinical trials are needed.

The antioxidant N-Acetyl cysteine (NAC) is frequently used as a mucolytic, but has spiked recent interest as antioxidant due to its ability to increase glutathione levels and inhibit H₂O₂-induced damage. Supplementation of oral NAC was linked to significantly increased blood glutathione levels and decreased neutrophils, IL-8, and elastase activity in sputum of CF patients (Tirouvanziam et al., 2006) A randomized double-blind placebo-controlled trial including 70 CF patients for 24 weeks showed stability or a slight increase in spirometric lung function in NAC treated participants compared to the control group (Conrad et al., 2015). A second open-label randomized controlled trial demonstrated a non-significant improvement in lung function in adults with CF and chronic Pseudomonas infection (Skov et al., 2015). P3001, a mucolytic agent was also assessed and directly compared with NAC in a more recent study using both in vitro and in vivo CF models. Results indicated that P3001 acted faster and was more effective than NAC and DNAse, but investigators did not study its anti-oxidant or anti-inflammatory properties (Ehre et al., 2019). Since glutathione is transported by CFTR (Linsdell and Hanrahan, 1998), CFTR defects could potentially decrease levels of this antioxidant in the airway epithelium increasing susceptibility to oxidative stress. Indeed, decreased glutathione levels have been observed in CF mouse models and patients (Roum et al., 1985; Velsor et al., 2001). A small pilot study using twice daily treatment of aerosolized glutathione in CF patients led to a reduction in superoxide production, but no changes in oxidative stress markers in bronchoalveolar lavage fluid (Bishop et al., 2005; Hartl et al., 2005). A more recent Cochrane meta-analysis summarized antioxidant therapy approaches in CF and concluded that there does not seem to be a beneficial effect of antioxidant micronutrients on clinical outcomes; but oral supplementation with glutathione showed some benefit to lung function, nutritional status, and decrease in oxidative stress (Ciofu et al., 2019). Nevertheless, due to concurrent treatments including intensive antibiotic therapies, there is not sufficient evidence yet justifying their use in the CF population without larger trials and longer follow up.

Therapeutic use of protease inhibitors has been investigated in CF since 1990. Several groups demonstrated that α₁-antitrypsin delivered as an aerosol formulary decreases inflammatory markers and neutrophils (McElvaney et al., 1991; Griese et al., 2007). rSLPI and EPI-hNE4 are two neutrophil elastase inhibitors, which have shown beneficial effects in CF, but large cohort trials are still lacking (McElvaney et al., 1993; Grimbert et al., 2003).

Other potential anti-inflammatories are also being investigated. SB-656933, a CXCR2 antagonist, has shown a trend toward attenuating airway inflammation (Moss et al., 2013). Low-dose cyclosporin A was characterized as a potential steroid sparing agent in a small case series (Bhal et al., 2001). Furthermore, methotrexate was studied as a potential anti-inflammatory agent in cystic fibrosis, but studies were inconclusive with one showing beneficial effects on lung function and total serum immunoglobulin levels, whereas another study showed less tolerance and increased exacerbations (Ballmann et al., 2003; Oermann and Wheeler C, 2007).

Micro RNAs as a potential anti-inflammatory approach have recently become a focus of interest. mi-RNAs have been implicated in various diseases including cystic fibrosis (Bardin et al., 2019; Bartoszewska et al., 2017). Vencken et al. suggested the use of nebulized lipid-polymer hybrid nanoparticles for the delivery of a therapeutic anti-inflammatory microRNA, miR-17, to reduce IL-8 secretion, which was successfully tested in vitro (Vencken et al., 2019) In addition, targeting miRNAs to restore CFTR activity has also been suggested as a novel therapeutic strategy (De Santi et al., 2020). Please see Table 1 for a summary of the evidence for accelerated aging in CF shown in in vitro and in vivo studies.

Conclusion and Further Directions

Increasing evidence suggests that accelerated aging processes are involved in CF lung pathology. Based on the current state of research summarized in the paragraphs above, it appears sufficiently established that accelerated aging in CF patients is not only a consequence of chronic lung inflammation, but aging-associated processes are also driving disease progression. Of the ten hallmarks of aging, according to recent literature all but stem cell depletion and telomere attrition appear to be involved to varying degrees in CF lung disease (cp. Figure 1). For some hallmarks there is already considerable data on the specific mechanisms of their pathologic involvement, as in the case of altered proteostasis and intercellular communication. Others, such as mitochondrial dysfunction, deregulated nutrient sensing and cellular senescence, have been indicated to play a role in CF lung pathology and accelerated aging, but further research is needed to elucidate underlying pathomechanisms. And although each of the ten hallmarks was discussed individually, they should be considered as interdependent processes that influence each other.

Growing evidence on the role of accelerated aging processes in CF lung disease and progress in deciphering involved mechanisms also provide new therapeutic targets for future treatment strategy complementing established therapies as summarized in Therapeutic Implications. Some therapies targeting the ten hallmarks of aging are already in clinical use, and further can be expected to follow which may aid further reducing mortality and improving quality of life in CF patients.

References

• 1

  Aldámiz-EchevarríaL.PrietoJ. A.AndradeF.ElorzJ.SojoA.LageS.et al (2009). Persistence of essential fatty acid deficiency in cystic fibrosis despite nutritional therapy. Pediatr. Res.66 (5), 585–589. 10.1203/pdr.0b013e3181b4e8d3

  • CrossRef
  • Google Scholar

• 2

  AoshibaK.YasudaK.YasuiS.TamaokiJ.NagaiA. (2001). Serine proteases increase oxidative stress in lung cells. Am. J. Physiology-Lung Cell Mol. Physiol.281 (3), L556–L564. 10.1152/ajplung.2001.281.3.l556

  • CrossRef
  • Google Scholar

• 3

  ArkwrightP. D.LaurieS.SuperM.PravicaV.SchwarzM. J.WebbA. K.et al (2000). TGF-beta 1 genotype and accelerated decline in lung function of patients with cystic fibrosis. Thorax55 (6), 459–462. 10.1136/thorax.55.6.459

  • CrossRef
  • Google Scholar

• 4

  AshapkinV. V.KutuevaL. I.VanyushinB. F. (2017). Aging as an epigenetic phenomenon. Curr. Genomics18 (5), 385–407. 10.2174/1389202918666170412112130

  • CrossRef
  • Google Scholar

• 5

  AuerbachH.KirkpatrickJ.WilliamsM.ColtenH. (1985). Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. The Lancet326 (8457), 686–688. 10.1016/s0140-6736(85)92929-0

  • CrossRef
  • Google Scholar

• 6

  BalchW. E.RothD. M.HuttD. M. (2011). Emergent properties of proteostasis in managing cystic fibrosis. Cold Spring Harb Perspect. Biol.3 (2). 10.1101/cshperspect.a004499

  • CrossRef
  • Google Scholar

• 7

  BallmannM.JungeS.von der HardtH. (2003). Low-dose methotrexate for advanced pulmonary disease in patients with cystic fibrosis. Respir. Med.97 (5), 498–500. 10.1053/rmed.2002.1471

  • CrossRef
  • Google Scholar

• 8

  BardinP.FoussignièreT.RousseletN.RebeyrolC.PorterJ. C.CorvolH.et al (2019). miR-636: a newly-identified actor for the regulation of pulmonary inflammation in cystic fibrosis. Front. Immunol.10, 2643. 10.3389/fimmu.2019.02643

  • CrossRef
  • Google Scholar

• 9

  BartoszewskaS.KamyszW.JakielaB.SanakM.KróliczewskiJ.BebokZ.et al (2017). miR-200b downregulates CFTR during hypoxia in human lung epithelial cells. Cell Mol Biol Lett22, 23. 10.1186/s11658-017-0054-0

  • CrossRef
  • Google Scholar

• 10

  BartoszewskiR.RabA.JurkuvenaiteA.MazurM.WakefieldJ.CollawnJ. F.et al (2008). Activation of the unfolded protein response by ΔF508 CFTR. Am. J. Respir. Cel Mol Biol39 (4), 448–457. 10.1165/rcmb.2008-0065oc

  • CrossRef
  • Google Scholar

• 11

  BeharryS.AckerleyC.CoreyM.KentG.HengY.-M.ChristensenH.et al (2007). Long-term docosahexaenoic acid therapy in a congenic murine model of cystic fibrosis. Am. J. Physiology-Gastrointestinal Liver Physiol.292 (3), G839–G848. 10.1152/ajpgi.00582.2005

  • CrossRef
  • Google Scholar

• 12

  BergerS. L.KouzaridesT.ShiekhattarR.ShilatifardA. (2009). An operational definition of epigenetics. Genes Development23 (7), 781–783. 10.1101/gad.1787609

  • CrossRef
  • Google Scholar

• 13

  BezzerriV.PiacenzaF.CaporelliN.MalavoltaM.ProvincialiM.CipolliM. (2019). Is cellular senescence involved in cystic fibrosis?Respir. Res.20 (1), 32. 10.1186/s12931-019-0993-2

  • CrossRef
  • Google Scholar

• 14

  BhalG. K.MaguireS. A.BowlerI. M. (2001). Use of cyclosporin A as a steroid sparing agent in cystic fibrosis. Arch. Dis. Child.84 (1), 89. 10.1136/adc.84.1.89

  • CrossRef
  • Google Scholar

• 15

  BhattacharyyaS.BalakathiresanN. S.DalgardC.GuttiU.ArmisteadD.JozwikC.et al (2011). Elevated miR-155 promotes inflammation in cystic fibrosis by driving hyperexpression of interleukin-8. J. Biol. Chem.286 (13), 11604–11615. 10.1074/jbc.m110.198390

  • CrossRef
  • Google Scholar

• 16

  BishopC.HudsonV. M.HiltonS. C.WildeC. (2005). A pilot study of the effect of inhaled buffered reduced glutathione on the clinical status of patients with cystic fibrosis. Chest127 (1), 308–317. 10.1378/chest.127.1.308

  • CrossRef
  • Google Scholar

• 17

  BlackburnE. H.GreiderC. W.SzostakJ. W. (2006). Telomeres and telomerase: the path from maize, Tetrahymena and yeast to human cancer and aging. Nat. Med.12 (10), 1133–1138. 10.1038/nm1006-1133

  • CrossRef
  • Google Scholar

• 18

  BonfieldT. L.KonstanM. W.BergerM. (1999). Altered respiratory epithelial cell cytokine production in cystic fibrosis☆☆☆★. J. Allergy Clin. Immunol.104 (1), 72–78. 10.1016/s0091-6749(99)70116-8

  • CrossRef
  • Google Scholar

• 19

  BorcherdingD. C.SiefertM. E.LinS.BrewingtonJ.SadekH.ClancyJ. P.et al (2019). Clinically approved CFTR modulators rescue Nrf2 dysfunction in cystic fibrosis airway epithelia. J. Clin. Invest.129 (8), 3448–3463. 10.1172/jci96273

  • CrossRef
  • Google Scholar

• 20

  BoucherR. C. (2007). Cystic fibrosis: a disease of vulnerability to airway surface dehydration. Trends Mol. Med.13 (6), 231–240. 10.1016/j.molmed.2007.05.001

  • CrossRef
  • Google Scholar

• 21

  BrownR. K.KellyF. J. (1994). Evidence for increased oxidative damage in patients with cystic fibrosis. Pediatr. Res.36 (4), 487–492. 10.1203/00006450-199410000-00013

  • CrossRef
  • Google Scholar

• 22

  BrownR. K.McBurneyA.LunecJ.KellyF. J. (1995). Oxidative damage to DNA in patients with cystic fibrosis. Free Radic. Biol. Med.18 (4), 801–806. 10.1016/0891-5849(94)00172-g

  • CrossRef
  • Google Scholar

• 23

  ChapmanJ.FielderE.PassosJ. F. (2019). Mitochondrial dysfunction and cell senescence: deciphering a complex relationship. FEBS Lett.593 (13), 1566–1579. 10.1002/1873-3468.13498

  • CrossRef
  • Google Scholar

• 24

  ChenT.ShenL.YuJ.WanH.GuoA.ChenJ.et al (2011). Rapamycin and other longevity-promoting compounds enhance the generation of mouse induced pluripotent stem cells. Aging Cell10 (5), 908–911. 10.1111/j.1474-9726.2011.00722.x

  • CrossRef
  • Google Scholar

• 25

  ChenY.ArmstrongD. A.SalasL. A.HazlettH. F.NymonA. B.DessaintJ. A.et al (2018). Genome-wide DNA methylation profiling shows a distinct epigenetic signature associated with lung macrophages in cystic fibrosis. Clin. Epigenetics10 (1), 152. 10.1186/s13148-018-0580-2

  • CrossRef
  • Google Scholar

• 26

  ChengS. H.GregoryR. J.MarshallJ.PaulS.SouzaD. W.WhiteG. A.et al (1990). Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell63 (4), 827–834. 10.1016/0092-8674(90)90148-8

  • CrossRef
  • Google Scholar

• 27

  ChmielJ. F.KonstanM. W.KnesebeckJ. E.HilliardJ. B.BonfieldT. L.DawsonD. V.et al (1999). IL-10 attenuates excessive inflammation in ChronicPseudomonasInfection in mice. Am. J. Respir. Crit. Care Med.160 (6), 2040–2047. 10.1164/ajrccm.160.6.9901043

  • CrossRef
  • Google Scholar

• 28

  ChoS. J.Stout-DelgadoH. W. (2020). Aging and lung disease. Annu. Rev. Physiol.82, 433–459. 10.1146/annurev-physiol-021119-034610

  • CrossRef
  • Google Scholar

• 29

  ChuaF.LaurentG. J. (2006). Neutrophil elastase: mediator of extracellular matrix destruction and accumulation. Proc. Am. Thorac. Soc.3 (5), 424–427. 10.1513/pats.200603-078aw

  • CrossRef
  • Google Scholar

• 30

  CiofuO.LykkesfeldtJ.LykkesfeldtJ. (2019). Antioxidant supplementation for lung disease in cystic fibrosis. Cochrane Database Syst. Rev.10, CD007020. 10.1002/14651858.CD007020.pub3

  • CrossRef
  • Google Scholar

• 31

  ConradC.LympJ.ThompsonV.DunnC.DaviesZ.ChatfieldB.et al (2015). Long-term treatment with oral N-acetylcysteine: affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial. J. Cystic Fibrosis14 (2), 219–227. 10.1016/j.jcf.2014.08.008

  • CrossRef
  • Google Scholar

• 32

  DanahayH. L.LilleyS.FoxR.CharltonH.SabaterJ.ButtonB.et al (2020). TMEM16A potentiation: a novel therapeutic approach for the treatment of cystic fibrosis. Am. J. Respir. Crit. Care Med.201 (8), 946–954. 10.1164/rccm.201908-1641oc

  • CrossRef
  • Google Scholar

• 33

  DaviesJ. C.MoskowitzS. M.BrownC.HorsleyA.MallM. A.McKoneE. F.et al (2018). VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. N. Engl. J. Med.379 (17), 1599–1611. 10.1056/nejmoa1807119

  • CrossRef
  • Google Scholar

• 34

  De BoeckK.VermeulenF.WanyamaS.ThomasM. (2011). Inhaled corticosteroids and lower lung function decline in young children with cystic fibrosis. Eur. Respir. J.37 (5), 1091–1095. 10.1183/09031936.00077210

  • CrossRef
  • Google Scholar

• 35

  De SantiC.Fernández FernándezE.GaulR.VenckenS.GlasgowA.OglesbyI. K.et al (2020). Precise targeting of miRNA sites restores CFTR activity in CF bronchial epithelial cells. Mol. Ther.28 (4), 1190–1199. 10.1016/j.ymthe.2020.02.001

  • CrossRef
  • Google Scholar

• 36

  DodgeJ. A.LewisP. A.StantonM.WilsherJ. (2007). Cystic fibrosis mortality and survival in the UK: 1947-2003. Eur. Respir. J.29 (3), 522–526. 10.1183/09031936.00099506

  • CrossRef
  • Google Scholar

• 37

  dos SantosG.KutuzovM. A.RidgeK. M. (2012). The inflammasome in lung diseases. Am. J. Physiology-Lung Cell Mol. Physiol.303 (8), L627–L633. 10.1152/ajplung.00225.2012

  • CrossRef
  • Google Scholar

• 38

  DunzendorferS.RothbucherD.SchratzbergerP.ReinischN.KählerC. M.WiedermannC. J. (1997). Mevalonate-dependent inhibition of transendothelial migration and chemotaxis of human peripheral blood neutrophils by pravastatin. Circ. Res.81 (6), 963–969. 10.1161/01.res.81.6.963

  • CrossRef
  • Google Scholar

• 39

  DurieuI.PeyrolS.GindreD.BellonG.DurandD. V.PachecoY. (1998). Subepithelial fibrosis and degradation of the bronchial extracellular matrix in cystic fibrosis. Am. J. Respir. Crit. Care Med.158 (2), 580–588. 10.1164/ajrccm.158.2.9707126

  • CrossRef
  • Google Scholar

• 40

  EhreC.RushtonZ. L.WangB.HothemL. N.MorrisonC. B.FontanaN. C.et al (2019). An improved inhaled mucolytic to treat airway muco-obstructive diseases. Am. J. Respir. Crit. Care Med.199 (2), 171–180. 10.1164/rccm.201802-0245oc

  • CrossRef
  • Google Scholar

• 41

  EigenH.RosensteinB. J.FitzSimmonsS.SchidlowD. V. (1995). A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. J. Pediatr.126 (4), 515–523. 10.1016/s0022-3476(95)70343-8

  • CrossRef
  • Google Scholar

• 42

  ElbornJ. S. (2016). Cystic fibrosis. The Lancet388 (10059), 2519–2531. 10.1016/s0140-6736(16)00576-6

  • CrossRef
  • Google Scholar

• 43

  EspositoS.ToscoA.VillellaV. R.RaiaV.KroemerG.MaiuriL. (2016). Manipulating proteostasis to repair the F508del-CFTR defect in cystic fibrosis. Mol. Cel Pediatr3 (1), 13. 10.1186/s40348-016-0040-z

  • CrossRef
  • Google Scholar

• 44

  EveraertsS.LammertynE.MartensD. S.SadeleerL. D.MaesK.GoldschmedingR.et al (2018). The aging lung: tissue telomere shortening in health and disease. Respir. Res.19 (1), 95. 10.1186/s12931-018-0794-z

  • CrossRef
  • Google Scholar

• 45

  FerrettiS.BonneauO.DuboisG. R.JonesC. E.TrifilieffA. (2003). IL-17, produced by lymphocytes and neutrophils, is necessary for lipopolysaccharide-induced airway neutrophilia: IL-15 as a possible trigger. J. Immunol.170 (4), 2106–2112. 10.4049/jimmunol.170.4.2106

  • CrossRef
  • Google Scholar

• 46

  FinkA. K.YanikE. L.MarshallB. C.WilschanskiM.LynchC. F.AustinA. A.et al (2017). Cancer risk among lung transplant recipients with cystic fibrosis. J. Cystic Fibrosis16 (1), 91–97. 10.1016/j.jcf.2016.07.011

  • CrossRef
  • Google Scholar

• 47

  FischerB. M.WongJ. K.DeganS.KummarapuruguA. B.ZhengS.HaridassP.et al (2013). Increased expression of senescence markers in cystic fibrosis airways. Am. J. Physiology-Lung Cell Mol. Physiol.304 (6), L394–L400. 10.1152/ajplung.00091.2012

  • CrossRef
  • Google Scholar

• 48

  FischerB. M.ZhengS.FanR.VoynowJ. A. (2007). Neutrophil elastase inhibition of cell cycle progression in airway epithelial cells in vitro is mediated by p27kip1. Am. J. Physiology-Lung Cell Mol. Physiol.293 (3), L762–L768. 10.1152/ajplung.00067.2007

  • CrossRef
  • Google Scholar

• 49

  FlumeP. A.O'SullivanB. P.RobinsonK. A.GossC. H.MogayzelP. J.Willey-CourandD. B.et al (2007). Cystic fibrosis pulmonary guidelines. Am. J. Respir. Crit. Care Med.176 (10), 957–969. 10.1164/rccm.200705-664oc

  • CrossRef
  • Google Scholar

• 50

  FranceschiC.CampisiJ. (2014). Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. Journals Gerontol. Ser. A: Biol. Sci. Med. Sci.69 (Suppl. 1), S4–S9. 10.1093/gerona/glu057

  • CrossRef
  • Google Scholar

• 51

  FreedmanS. D.KatzM. H.ParkerE. M.LaposataM.UrmanM. Y.AlvarezJ. G. (1999). A membrane lipid imbalance plays a role in the phenotypic expression of cystic fibrosis in cftr-/- mice. Proc. Natl. Acad. Sci.96 (24), 13995–14000. 10.1073/pnas.96.24.13995

  • CrossRef
  • Google Scholar

• 52

  GaggarA.HectorA.BratcherP. E.MallM. A.GrieseM.HartlD. (2011). The role of matrix metalloproteinases in cystic fibrosis lung disease. Eur. Respir. J.38 (3), 721–727. 10.1183/09031936.00173210

  • CrossRef
  • Google Scholar

• 53

  GaggarA.LiY.WeathingtonN.WinklerM.KongM.JacksonP.et al (2007). Matrix metalloprotease-9 dysregulation in lower airway secretions of cystic fibrosis patients. Am. J. Physiology-Lung Cell Mol. Physiol.293 (1), L96–L104. 10.1152/ajplung.00492.2006

  • CrossRef
  • Google Scholar

• 54

  GonzaloS. (1985). Epigenetic alterations in aging. J. Appl. Physiol.109 (2), 586–597. 10.1152/japplphysiol.00238.2010

  • CrossRef
  • Google Scholar

• 55

  GorenjakV.PetrelisA. M.StathopoulouM. G.Visvikis-SiestS. (2020). Telomere length determinants in childhood. Clin. Chem. Lab. Med.58 (2), 162–177. 10.1515/cclm-2019-0235

  • CrossRef
  • Google Scholar

• 56

  GrasemannH.GrasemannC.KurtzF.Tietze-SchillingsG.VesterU.RatjenF. (2005a). Oral L-arginine supplementation in cystic fibrosis patients: a placebo-controlled study. Eur. Respir. J.25 (1), 62–68. 10.1183/09031936.04.00086104

  • CrossRef
  • Google Scholar

• 57

  GrasemannH.SchwiertzR.MatthiesenS.RackéK.RatjenF. (2005b). Increased arginase activity in cystic fibrosis airways. Am. J. Respir. Crit. Care Med.172 (12), 1523–1528. 10.1164/rccm.200502-253oc

  • CrossRef
  • Google Scholar

• 58

  GrieseM.LatzinP.KapplerM.WeckerleK.HeinzlmaierT.BernhardtT.et al (2007). alpha1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients. Eur. Respir. J.29 (2), 240–250. 10.1183/09031936.00047306

  • CrossRef
  • Google Scholar

• 59

  GrimbertD.VecellioL.DelépineP.AttucciS.BoissinotE.PoncinA.et al (2003). Characteristics of EPI-hNE4 aerosol: a new elastase inhibitor for treatment of cystic fibrosis. J. Aerosol Med.16 (2), 121–129. 10.1089/089426803321919889

  • CrossRef
  • Google Scholar

• 60

  HallowsK. R.RaghuramV.KempB. E.WittersL. A.FoskettJ. K. (2000). Inhibition of cystic fibrosis transmembrane conductance regulator by novel interaction with the metabolic sensor AMP-activated protein kinase. J. Clin. Invest.105 (12), 1711–1721. 10.1172/jci9622

  • CrossRef
  • Google Scholar

• 61

  HarrisW. T.MuhlebachM. S.OsterR. A.KnowlesM. R.NoahT. L. (2009). Transforming growth factor-β1 in bronchoalveolar lavage fluid from children with cystic fibrosis. Pediatr. Pulmonol.44 (11), 1057–1064. 10.1002/ppul.21079

  • CrossRef
  • Google Scholar

• 62

  HartlD.StarostaV.MaierK.Beck-SpeierI.RebhanC.BeckerB. F.et al (2005). Inhaled glutathione decreases PGE2 and increases lymphocytes in cystic fibrosis lungs. Free Radic. Biol. Med.39 (4), 463–472. 10.1016/j.freeradbiomed.2005.03.032

  • CrossRef
  • Google Scholar

• 63

  HaydarD.CoryT. J.BirketS. E.MurphyB. S.PennypackerK. R.SinaiA. P.et al (2019). Azithromycin polarizes macrophages to an M2 phenotype via inhibition of the STAT1 and NF-κB signaling pathways. J.I.203 (4), 1021–1030. 10.4049/jimmunol.1801228

  • CrossRef
  • Google Scholar

• 64

  HewittG.JurkD.MarquesF. D. M.Correia-MeloC.HardyT.GackowskaA.et al (2012). Telomeres are favoured targets of a persistent DNA damage response in ageing and stress-induced senescence. Nat. Commun.3, 708. 10.1038/ncomms1708

  • CrossRef
  • Google Scholar

• 65

  HilliardT. N.RegameyN.ShuteJ. K.NicholsonA. G.AltonE. W. F. W.BushA.et al (2007). Airway remodelling in children with cystic fibrosis. Thorax62 (12), 1074–1080. 10.1136/thx.2006.074641

  • CrossRef
  • Google Scholar

• 66

  HisertK. B.HeltsheS. L.PopeC.JorthP.WuX.EdwardsR. M.et al (2017). Restoring cystic fibrosis transmembrane conductance regulator function reduces airway bacteria and inflammation in people with cystic fibrosis and chronic lung infections. Am. J. Respir. Crit. Care Med.195 (12), 1617–1628. 10.1164/rccm.201609-1954oc

  • CrossRef
  • Google Scholar

• 67

  HodsonM. E.SimmondsN. J.WarwickW. J.TullisE.CastellaniC.AssaelB.et al (2008). An international/multicentre report on patients with cystic fibrosis (CF) over the age of 40 years. J. Cystic Fibrosis7 (6), 537–542. 10.1016/j.jcf.2008.06.003

  • CrossRef
  • Google Scholar

• 68

  HoganB. L. M.BarkauskasC. E.ChapmanH. A.EpsteinJ. A.JainR.HsiaC. C. W.et al (2014). Repair and regeneration of the respiratory system: complexity, plasticity, and mechanisms of lung stem cell function. Cell Stem Cell15 (2), 123–138. 10.1016/j.stem.2014.07.012

  • CrossRef
  • Google Scholar

• 69

  HoratiH.JanssensH. M.MargaroliC.VeltmanM.StolarczykM.KilgoreM. B.et al (2020). Airway profile of bioactive lipids predicts early progression of lung disease in cystic fibrosis. J. Cystic Fibrosis19 (6), 902–909. 10.1016/j.jcf.2020.01.010

  • CrossRef
  • Google Scholar

• 70

  HunterM. J.TreharneK. J.WinterAKCassidyD. M.LandS. (2010). Expression of wild-type CFTR suppresses NF-kappaB-driven inflammatory signalling. PLoS One5 (7), e11598. 10.1371/journal.pone.0011598

  • CrossRef
  • Google Scholar

• 71

  Jarosz-GriffithsH. H.ScamblerT.WongC. H.Lara-ReynaS.HolbrookJ.MartinonF.et al (2020). Different CFTR modulator combinations downregulate inflammation differently in cystic fibrosis. Elife9. 10.7554/elife.54556

  • CrossRef
  • Google Scholar

• 72

  JeyapalanJ. C.FerreiraM.SedivyJ. M.HerbigU. (2007). Accumulation of senescent cells in mitotic tissue of aging primates. Mech. Ageing Development128 (1), 36–44. 10.1016/j.mad.2006.11.008

  • CrossRef
  • Google Scholar

• 73

  JonesM. J.GoodmanS. J.KoborM. S. (2015). DNA methylation and healthy human aging. Aging Cell14 (6), 924–932. 10.1111/acel.12349

  • CrossRef
  • Google Scholar

• 74

  JurkD.WilsonC.PassosJ. F.OakleyF.Correia-MeloC.GreavesL.et al (2014). Chronic inflammation induces telomere dysfunction and accelerates ageing in mice. Nat. Commun.2, 4172. 10.1038/ncomms5172

  • CrossRef
  • Google Scholar

• 75

  KeatingD.MarigowdaG.BurrL.DainesC.MallM. A.McKoneE. F.et al (2018). VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. N. Engl. J. Med.379 (17), 1612–1620. 10.1056/nejmoa1807120

  • CrossRef
  • Google Scholar

• 76

  KenyonC. J. (2010). The genetics of ageing. Nature464 (7288), 504–512. 10.1038/nature08980

  • CrossRef
  • Google Scholar

• 77

  KeremB.RommensJ.BuchananJ.MarkiewiczD.CoxT.ChakravartiA.et al (1989). Identification of the cystic fibrosis gene: genetic analysis. Science245 (4922), 1073–1080. 10.1126/science.2570460

  • CrossRef
  • Google Scholar

• 78

  Konstan MwD. G.LandsL. C.HilliardK. A.KokerP.BhattacharyaS.StaabA.et al (2005). Results of a phase II clinical trial of BIIL 284 BS (a LTB4 receptor antagonist) for the treatment of CF lung disease. Pediatr. Pulmonol40, 125–127.

  • Google Scholar

• 79

  KonstanM. W.KrenickyJ. E.HilliardK. A.HilliardJ. B. (2009). A pilot study evaluating the effect of pioglitazone, simvastatin and ibuprofen on neutrophil migration in vivo in healthy subjects. Pediatr. Pulmonol44, 289–290.

  • Google Scholar

• 80

  KonstanM. W.ByardP. J.HoppelC. L.DavisP. B. (1995). Effect of high-dose ibuprofen in patients with cystic fibrosis. N. Engl. J. Med.332 (13), 848–854. 10.1056/nejm199503303321303

  • CrossRef
  • Google Scholar

• 81

  KonstanM. W.KrenickyJ. E.FinneyM. R.KirchnerH. L.HilliardK. A.HilliardJ. B.et al (2003). Effect of ibuprofen on neutrophil migration in vivo in cystic fibrosis and healthy subjects. J. Pharmacol. Exp. Ther.306 (3), 1086–1091. 10.1124/jpet.103.052449

  • CrossRef
  • Google Scholar

• 82

  KonstanM. W.SchluchterM. D.XueW.DavisP. B. (2007). Clinical use of ibuprofen is associated with slower FEV1Decline in children with cystic fibrosis. Am. J. Respir. Crit. Care Med.176 (11), 1084–1089. 10.1164/rccm.200702-181oc

  • CrossRef
  • Google Scholar

• 83

  KonstanM. W.WalengaR. W.HilliardK. A.HilliardJ. B. (1993). Leukotriene B4Markedly elevated in the epithelial lining fluid of patients with cystic fibrosis. Am. Rev. Respir. Dis.148 (4 Pt 1), 896–901. 10.1164/ajrccm/148.4_pt_1.896

  • CrossRef
  • Google Scholar

• 84

  KoppB. T.FitchJ.JaramilloL.ShresthaC. L.Robledo-AvilaF.ZhangS.et al (2020). Whole-blood transcriptomic responses to lumacaftor/ivacaftor therapy in cystic fibrosis. J. Cystic Fibrosis19 (2), 245–254. 10.1016/j.jcf.2019.08.021

  • CrossRef
  • Google Scholar

• 85

  KraynackN. C.CoreyD. A.ElmerH. L.KelleyT. J. (2002). Mechanisms of NOS2 regulation by Rho GTPase signaling in airway epithelial cells. Am. J. Physiology-Lung Cell Mol. Physiol.283 (3), L604–L611. 10.1152/ajplung.00459.2001

  • CrossRef
  • Google Scholar

• 86

  LammertynE. M. D.ColpaertK.GoeminneP.ProesmansM.VanaudenaerdeB.NawrotT.et al (2017). The association between leukocyte telomere length, telomere attrition and disease severity in cystic fibrosis patients. Eur. Respir. J., OA4402.

  • Google Scholar

• 87

  LandsL. C.MilnerR.CantinA. M.MansonD.CoreyM. (2007). High-dose ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial. J. Pediatr.151 (3), 249–254. 10.1016/j.jpeds.2007.04.009

  • CrossRef
  • Google Scholar

• 88

  Lara-ReynaS.HolbrookJ.Jarosz-GriffithsH. H.PeckhamD.McDermottM. F. (2020). Dysregulated signalling pathways in innate immune cells with cystic fibrosis mutations. Cell. Mol. Life Sci.77 (22), 4485–4503. 10.1007/s00018-020-03540-9

  • CrossRef
  • Google Scholar

• 89

  Le GarsM.DescampsD.RousselD.SaussereauE.GuillotL.RuffinM.et al (2013). Neutrophil elastase degrades cystic fibrosis transmembrane conductance regulator via calpains and disables channel FunctionIn VitroandIn vivo. Am. J. Respir. Crit. Care Med.187 (2), 170–179. 10.1164/rccm.201205-0875oc

  • CrossRef
  • Google Scholar

• 90

  LevineM. E.LuA. T.QuachA.ChenB. H.AssimesT. L.BandinelliS.et al (2018). An epigenetic biomarker of aging for lifespan and healthspan. Aging10 (4), 573–591. 10.18632/aging.101414

  • CrossRef
  • Google Scholar

• 91

  LiJ.ZhangJ. T.JiangX.ShiX.ShenJ.FengF.et al (2015). The cystic fibrosis transmembrane conductance regulator as a biomarker in non-small cell lung cancer. Int. J. Oncol.46 (5), 2107–2115. 10.3892/ijo.2015.2921

  • CrossRef
  • Google Scholar

• 92

  LinsdellP.HanrahanJ. W. (1998). Glutathione permeability of CFTR. Am. J. Physiology-Cell Physiol.275 (1), C323–C326. 10.1152/ajpcell.1998.275.1.c323

  • CrossRef
  • Google Scholar

• 93

  Lopes-PachecoM.BoinotC.SabirzhanovaI.MoralesM. M.GugginoW. B.CebotaruL. (2015). Combination of correctors rescue df508-CFTR by reducing its association with Hsp40 and Hsp27. J. Biol. Chem.290 (42), 25636–25645. 10.1074/jbc.m115.671925

  • CrossRef
  • Google Scholar

• 94

  Lopes-PachecoM.SabirzhanovaI.RapinoD.MoralesM. M.GugginoW. B.CebotaruL. (2016). Correctors rescue CFTR mutations in nucleotide-binding domain 1 (NBD1) by modulating proteostasis. Chembiochem17 (6), 493–505. 10.1002/cbic.201500620

  • CrossRef
  • Google Scholar

• 95

  López-OtínC.BlascoM. A.PartridgeL.SerranoM.KroemerG. (2013). The hallmarks of aging. Cell153 (6), 1194–1217. 10.1016/j.cell.2013.05.039

  • CrossRef
  • Google Scholar

• 96

  LucianiA.VillellaV. R.EspositoS.GavinaM.RussoI.SilanoM.et al (2012). Targeting autophagy as a novel strategy for facilitating the therapeutic action of potentiators on ΔF508 cystic fibrosis transmembrane conductance regulator. Autophagy8 (11), 1657–1672. 10.4161/auto.21483

  • CrossRef
  • Google Scholar

• 97

  LucianiA.VillellaV. R.VasaturoA.GiardinoI.RaiaV.Pettoello-MantovaniM.et al (2009). SUMOylation of tissue transglutaminase as link between oxidative stress and inflammation. J. Immunol.183 (4), 2775–2784. 10.4049/jimmunol.0900993

  • CrossRef
  • Google Scholar

• 98

  LyK.SmithM. P.ThibodeauxQ.ReddyV.LiaoW.BhutaniT. (2019). Anti IL-17 in psoriasis. Expert Rev. Clin. Immunol.15 (11), 1185–1194. 10.1080/1744666x.2020.1679625

  • CrossRef
  • Google Scholar

• 99

  MacKenzieT.GiffordA. H.SabadosaK. A.QuintonH. B.KnappE. A.GossC. H.et al (2014). Longevity of patients with cystic fibrosis in 2000 to 2010 and beyond: survival analysis of the Cystic Fibrosis Foundation patient registry. Ann. Intern. Med.161 (4), 233–241. 10.7326/m13-0636

  • CrossRef
  • Google Scholar

• 100

  MagalhãesM.TostJ.PineauF.RivalsI.BusatoF.AlaryN.et al (2018). Dynamic changes of DNA methylation and lung disease in cystic fibrosis: lessons from a monogenic disease. Epigenomics10 (8), 1131–1145. 10.2217/epi-2018-0005

  • CrossRef
  • Google Scholar

• 101

  MaisonneuveP.MarshallB. C.KnappE. A.LowenfelsA. B. (2013). Cancer risk in cystic fibrosis: a 20-year nationwide study from the United States. J. Natl. Cancer Inst.105 (2), 122–129. 10.1093/jnci/djs481

  • CrossRef
  • Google Scholar

• 102

  MallM.GrubbB. R.HarkemaJ. R.O'NealW. K.BoucherR. C. (2004). Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice. Nat. Med.10 (5), 487–493. 10.1038/nm1028

  • CrossRef
  • Google Scholar

• 103

  ManzanaresD.KrickS.BaumlinN.DennisJ. S.TyrrellJ.TarranR.et al (2015). Airway surface dehydration by transforming growth factor β (TGF-β) in cystic fibrosis is due to decreased function of a voltage-dependent potassium channel and can Be rescued by the drug pirfenidone. J. Biol. Chem.290 (42), 25710–25716. 10.1074/jbc.m115.670885

  • CrossRef
  • Google Scholar

• 104

  MartinsR.LithgowG. J.LinkW. (2016). Long live FOXO : unraveling the role of FOXO proteins in aging and longevity. Aging Cell15 (2), 196–207. 10.1111/acel.12427

  • CrossRef
  • Google Scholar

• 105

  MatsuiH.GrubbB. R.TarranR.RandellS. H.GatzyJ. T.DavisC. W.et al (1998). Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell95 (7), 1005–1015. 10.1016/s0092-8674(00)81724-9

  • CrossRef
  • Google Scholar

• 106

  MayerM. L.BlohmkeC. J.FalsafiR.FjellC. D.MaderaL.TurveyS. E.et al (2013). Rescue of dysfunctional autophagy attenuates hyperinflammatory responses from cystic fibrosis cells. J.I.190 (3), 1227–1238. 10.4049/jimmunol.1201404

  • CrossRef
  • Google Scholar

• 107

  McCuaigS.MartinJ. G. (2013). How the airway smooth muscle in cystic fibrosis reacts in proinflammatory conditions: implications for airway hyper-responsiveness and asthma in cystic fibrosis. Lancet Respir. Med.1 (2), 137–147. 10.1016/s2213-2600(12)70058-9

  • CrossRef
  • Google Scholar

• 108

  McElvaneyN. G.DoujaijiB.MoanM. J.BurnhamM. R.WuM. C.CrystalR. G. (1993). Pharmacokinetics of recombinant secretory leukoprotease inhibitor aerosolized to normals and individuals with cystic fibrosis. Am. Rev. Respir. Dis.148 (4 Pt 1), 1056–1060. 10.1164/ajrccm/148.4_pt_1.1056

  • CrossRef
  • Google Scholar

• 109

  McElvaneyN. G.HubbardR. C.BirrerP.CrystalR. G.ChernickM. S.FrankM. M.et al (1991). Aerosol α1 -antitrypsin treatment for cystic fibrosis. The Lancet337 (8738), 392–394. 10.1016/0140-6736(91)91167-s

  • CrossRef
  • Google Scholar

• 110

  McElvaneyO. J.ZaslonaZ.Becker-FleglerK.Palsson-McDermottE. M.BolandF.GunaratnamC.et al (2019). Specific inhibition of the NLRP3 inflammasome as an antiinflammatory strategy in cystic fibrosis. Am. J. Respir. Crit. Care Med.200 (11), 1381–1391. 10.1164/rccm.201905-1013oc

  • CrossRef
  • Google Scholar

• 111

  MeinersS.EickelbergO.KönigshoffM. (2015). Hallmarks of the ageing lung. Eur. Respir. J.45 (3), 807–827. 10.1183/09031936.00186914

  • CrossRef
  • Google Scholar

• 112

  MeyerK. C.RosenthalN. S.SoergelP.PetersonK. (1998). Neutrophils and low-grade inflammation in the seemingly normal aging human lung. Mech. Ageing Development104 (2), 169–181. 10.1016/s0047-6374(98)00065-7

  • CrossRef
  • Google Scholar

• 113

  MiddletonP. G.MallM. A.DřevínekP.LandsL. C.McKoneE. F.PolineniD.et al (2019). Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. N. Engl. J. Med.381 (19), 1809–1819. 10.1056/nejmoa1908639

  • CrossRef
  • Google Scholar

• 114

  MingioneA.Dei CasM.BonezziF.CarettiA.PiccoliM.AnastasiaL.et al (2020). Inhibition of sphingolipid synthesis as a phenotype-modifying therapy in cystic fibrosis. Cell Physiol Biochem54 (1), 110–125. 10.33594/000000208

  • CrossRef
  • Google Scholar

• 115

  MontaniniL.SmerieriA.GullìM.CirilloF.PisiG.SartoriC.et al (2016). miR-146a, miR-155, miR-370, and miR-708 are CFTR-dependent, predicted FOXO1 regulators and change at onset of CFRDs. J. Clin. Endocrinol. Metab.101 (12), 4955–4963. 10.1210/jc.2016-2431

  • CrossRef
  • Google Scholar

• 116

  MoraA. L.RojasM. (2013). Adult stem cells for chronic lung diseases. Respirology18 (7), 1041–1046. 10.1111/resp.12112

  • CrossRef
  • Google Scholar

• 117

  MoskalevA. A.ShaposhnikovM. V.PlyusninaE. N.ZhavoronkovA.BudovskyA.YanaiH.et al (2013). The role of DNA damage and repair in aging through the prism of Koch-like criteria. Ageing Res. Rev.12 (2), 661–684. 10.1016/j.arr.2012.02.001

  • CrossRef
  • Google Scholar

• 118

  MossR. B.Mayer-HamblettN.WagenerJ.DainesC.HaleK.AhrensR.et al (2005). Randomized, double-blind, placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b in patients with mild to moderate cystic fibrosis lung disease. Pediatr. Pulmonol.39 (3), 209–218. 10.1002/ppul.20152

  • CrossRef
  • Google Scholar

• 119

  MossR. B.MistryS. J.KonstanM. W.PilewskiJ. M.KeremE.Tal-SingerR.et al (2013). Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis. J. Cystic Fibrosis12 (3), 241–248. 10.1016/j.jcf.2012.08.016

  • CrossRef
  • Google Scholar

• 120

  NakamuraH.YoshimuraK.McElvaneyN. G.CrystalR. G. (1992). Neutrophil elastase in respiratory epithelial lining fluid of individuals with cystic fibrosis induces interleukin-8 gene expression in a human bronchial epithelial cell line. J. Clin. Invest.89 (5), 1478–1484. 10.1172/jci115738

  • CrossRef
  • Google Scholar

• 121

  NaylorR. M.BakerD. J.van DeursenJ. M. (2013). Senescent cells: a novel therapeutic target for aging and age-related diseases. Clin. Pharmacol. Ther.93 (1), 105–116. 10.1038/clpt.2012.193

  • CrossRef
  • Google Scholar

• 122

  NicholsD.ChmielJ.BergerM. (2008). Chronic inflammation in the cystic fibrosis lung: alterations in inter- and intracellular signaling. Clinic Rev. Allerg Immunol.34 (2), 146–162. 10.1007/s12016-007-8039-9

  • CrossRef
  • Google Scholar

• 123

  NicholsD. P.Odem-DavisK.CogenJ. D.GossC. H.RenC. L.SkallandM.et al (2020). Pulmonary outcomes associated with long-term Azithromycin therapy in cystic fibrosis. Am. J. Respir. Crit. Care Med.201 (4), 430–437. 10.1164/rccm.201906-1206oc

  • CrossRef
  • Google Scholar

• 124

  OermannC. M. K. M.Wheeler CCumming. S. (2007). A pilot study evaluating the potential use of low-dose methotrexate as an anti-inflammatory therapy for cystic fibrosis lung disease. Pediatr. Pulmonol42, 292–293.

  • Google Scholar

• 125

  OhJ.LeeY. D.WagersA. J. (2014). Stem cell aging: mechanisms, regulators and therapeutic opportunities. Nat. Med.20 (8), 870–880. 10.1038/nm.3651

  • CrossRef
  • Google Scholar

• 126

  PankowS.BambergerC.CalzolariD.Martínez-BartoloméS.Lavallée-AdamM.BalchW. E.et al (2015). ∆F508 CFTR interactome remodelling promotes rescue of cystic fibrosis. Nature528 (7583), 510–516. 10.1038/nature15729

  • CrossRef
  • Google Scholar

• 127

  ParikhP.WicherS.KhandalavalaK.PabelickC. M.BrittR. D.PrakashY. S. (2019). Cellular senescence in the lung across the age spectrum. Am. J. Physiology-Lung Cell Mol. Physiol.316 (5), L826–L842. 10.1152/ajplung.00424.2018

  • CrossRef
  • Google Scholar

• 128

  ParkerM. W.RossiD.PetersonM.SmithK.SikströmK.WhiteE. S.et al (2014). Fibrotic extracellular matrix activates a profibrotic positive feedback loop. J. Clin. Invest.124 (4), 1622–1635. 10.1172/jci71386

  • CrossRef
  • Google Scholar

• 129

  PerezA.van HeeckerenA. M.NicholsD.GuptaS.EastmanJ. F.DavisP. B. (2008). Peroxisome proliferator-activated receptor-γ in cystic fibrosis lung epithelium. Am. J. Physiology-Lung Cell Mol. Physiol.295 (2), L303–L313. 10.1152/ajplung.90276.2008

  • CrossRef
  • Google Scholar

• 130

  Peterson-CarmichaelS. L.HarrisW. T.GoelR.NoahT. L.JohnsonR.LeighM. W.et al (2009). Association of lower airway inflammation with physiologic findings in young children with cystic fibrosis. Pediatr. Pulmonol.44 (5), 503–511. 10.1002/ppul.21044

  • CrossRef
  • Google Scholar

• 131

  Petit-BertronA.-F.TabaryO.CorvolH.JacquotJ.ClémentA.CavaillonJ.-M.et al (2008). Circulating and airway neutrophils in cystic fibrosis display different TLR expression and responsiveness to interleukin-10. Cytokine41 (1), 54–60. 10.1016/j.cyto.2007.10.012

  • CrossRef
  • Google Scholar

• 132

  PrakashY. S.PabelickC. M.SieckG. C. (2017). Mitochondrial dysfunction in airway disease. Chest152 (3), 618–626. 10.1016/j.chest.2017.03.020

  • CrossRef
  • Google Scholar

• 133

  RegameyN.JefferyP. K.AltonE. W. F. W.BushA.DaviesJ. C. (2011). Airway remodelling and its relationship to inflammation in cystic fibrosis. Thorax66 (7), 624–629. 10.1136/thx.2009.134106

  • CrossRef
  • Google Scholar

• 134

  ReillyR.MrozM. S.DempseyE.WynneK.KeelyS. J.McKoneE. F.et al (2017). Targeting the PI3K/Akt/mTOR signalling pathway in Cystic Fibrosis. Sci. Rep.7 (1), 7642. 10.1038/s41598-017-06588z

  • CrossRef
  • Google Scholar

• 135

  RenC. L.PastaD. J.RasouliyanL.WagenerJ. S.KonstanM. W.MorganW. J. (2008). Relationship between inhaled corticosteroid therapy and rate of lung function decline in children with cystic fibrosis. J. Pediatr.153 (6), 746–751. 10.1016/j.jpeds.2008.07.010

  • CrossRef
  • Google Scholar

• 136

  RimessiA.BezzerriV.PatergnaniS.MarchiS.CabriniG.PintonP. (2015). Mitochondrial Ca2+-dependent NLRP3 activation exacerbates the Pseudomonas aeruginosa-driven inflammatory response in cystic fibrosis. Nat. Commun.6, 6201. 10.1038/ncomms7201

  • CrossRef
  • Google Scholar

• 137

  RobertsonK. D. (2005). DNA methylation and human disease. Nat. Rev. Genet.6 (8), 597–610. 10.1038/nrg1655

  • CrossRef
  • Google Scholar

• 138

  RoumJ. H.BuhlR.McElvaneyN. G.BorokZ.CrystalR. G. (1985). Systemic deficiency of glutathione in cystic fibrosis. J. Appl. Physiol.75 (6), 2419–2424. 10.1152/jappl.1993.75.6.24191993

  • CrossRef
  • Google Scholar

• 139

  RoweS. M.DainesC.RingshausenF. C.KeremE.WilsonJ.TullisE.et al (2017). Tezacaftor-Ivacaftor in residual-function heterozygotes with cystic fibrosis. N. Engl. J. Med.377 (21), 2024–2035. 10.1056/nejmoa1709847

  • CrossRef
  • Google Scholar

• 140

  RoweS. M.HeltsheS. L.GonskaT.DonaldsonS. H.BorowitzD.GelfondD.et al (2014). Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis. Am. J. Respir. Crit. Care Med.190 (2), 175–184. 10.1164/rccm.201404-0703oc

  • CrossRef
  • Google Scholar

• 141

  RuanX. Z.MoorheadJ. F.FernandoR.WheelerD. C.PowisS. H.VargheseZ. (2003). PPAR agonists protect mesangial cells from interleukin 1 -induced intracellular lipid accumulation by activating the ABCA1 cholesterol efflux pathway. J. Am. Soc. Nephrol.14 (3), 593–600. 10.1097/01.asn.0000050414.52908.da

  • CrossRef
  • Google Scholar

• 142

  SagelS. D.SontagM. K.WagenerJ. S.KapsnerR. K.OsbergI.AccursoF. J. (2002). Induced sputum inflammatory measures correlate with lung function in children with cystic fibrosis. J. Pediatr.141 (6), 811–817. 10.1067/mpd.2002.129847

  • CrossRef
  • Google Scholar

• 143

  ScamblerT.Jarosz-GriffithsH. H.Lara-ReynaS.PathakS.WongC.HolbrookJ.et al (2019). ENaC-mediated sodium influx exacerbates NLRP3-dependent inflammation in cystic fibrosis. Elife8. 10.7554/elife.49248

  • CrossRef
  • Google Scholar

• 144

  ScottM.De SarioA. (2020). DNA methylation changes in cystic fibrosis: cause or consequence?Clin. Genet.98 (1), 3–9. 10.1111/cge.13731

  • CrossRef
  • Google Scholar

• 145

  ScottP.AndersonK.SinghaniaM.CormierR. (2020). Cystic fibrosis, CFTR, and colorectal cancer. Int. J. Mol. Sci.21 (8). 10.3390/ijms21082891

  • CrossRef
  • Google Scholar

• 146

  SeilerF.HellbergJ.LepperP. M.KamyschnikowA.HerrC.BischoffM.et al (2013). FOXO transcription factors regulate innate immune mechanisms in respiratory epithelial cells. J.I.190 (4), 1603–1613. 10.4049/jimmunol.1200596

  • CrossRef
  • Google Scholar

• 147

  SimmondsN. J.CullinanP.HodsonM. E. (2009). Growing old with cystic fibrosis - the characteristics of long-term survivors of cystic fibrosis. Respir. Med.103 (4), 629–635. 10.1016/j.rmed.2008.10.011

  • CrossRef
  • Google Scholar

• 148

  SirinupongN.YangZ. (2015). Epigenetics in cystic fibrosis: epigenetic targeting of a genetic disease. Cdt16 (9), 976–987. 10.2174/1389450116666150416114514

  • CrossRef
  • Google Scholar

• 149

  SkovM.PresslerT.LykkesfeldtJ.PoulsenH. E.JensenP. Ø.JohansenH. K.et al (2015). The effect of short-term, high-dose oral N-acetylcysteine treatment on oxidative stress markers in cystic fibrosis patients with chronic P. aeruginosa infection - a pilot study. J. Cystic Fibrosis14 (2), 211–218. 10.1016/j.jcf.2014.09.015

  • CrossRef
  • Google Scholar

• 150

  SmerieriA.MontaniniL.MaiuriL.BernasconiS.StreetM. (2014). FOXO1 content is reduced in cystic fibrosis and increases with IGF-I treatment. Ijms15 (10), 18000–18022. 10.3390/ijms151018000

  • CrossRef
  • Google Scholar

• 151

  SnodgrassS. M.CihilK. M.CornuetP. K.MyerburgM. M.Swiatecka-UrbanA. (2013). Tgf-beta1 inhibits Cftr biogenesis and prevents functional rescue of DeltaF508-Cftr in primary differentiated human bronchial epithelial cells. PLoS One8 (5), e63167. 10.1371/journal.pone.0063167

  • CrossRef
  • Google Scholar

• 152

  SoltysJ.BonfieldT.ChmielJ.BergerM. (2002). Functional IL-10 deficiency in the lung of cystic fibrosis (cftr−/−) and IL-10 knockout mice causes increased expression and function of B7 costimulatory molecules on alveolar macrophages. J. Immunol.168 (4), 1903–1910. 10.4049/jimmunol.168.4.1903

  • CrossRef
  • Google Scholar

• 153

  StarostaV.RietschelE.PaulK.BaumannU.GrieseM. (2006). Oxidative changes of bronchoalveolar proteins in cystic fibrosis. Chest129 (2), 431–437. 10.1378/chest.129.2.431

  • CrossRef
  • Google Scholar

• 154

  StrubM. D.McCrayP. B.Jr. (2020). Transcriptomic and proteostasis networks of CFTR and the development of small molecule modulators for the treatment of cystic fibrosis lung disease. Genes (Basel)11 (5). 10.3390/genes11050546

  • CrossRef
  • Google Scholar

• 155

  SunH.HarrisW. T.KortykaS.KothaK.OstmannA. J.RezayatA.et al (2014). Tgf-beta downregulation of distinct chloride channels in cystic fibrosis-affected epithelia. PLoS One9 (9), e106842. 10.1371/journal.pone.0106842

  • CrossRef
  • Google Scholar

• 156

  TaamsL. S. (2020). Interleukin-17 in rheumatoid arthritis: trials and tribulations. J. Exp. Med.217 (3). 10.1084/jem.20192048

  • CrossRef
  • Google Scholar

• 157

  Taylor-CousarJ. L.MunckA.McKoneE. F.van der EntC. K.MoellerA.SimardC.et al (2017). Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del. N. Engl. J. Med.377 (21), 2013–2023. 10.1056/nejmoa1709846

  • CrossRef
  • Google Scholar

• 158

  TeramuraT.OnoderaY. (2018). Stem cell depletion by inflammation-associated miR-155. Aging10 (1), 17–18. 10.18632/aging.101374

  • CrossRef
  • Google Scholar

• 159

  ThanB. L.LinnekampJ. F.StarrT. K.LargaespadaD. A.RodA.ZhangY.et al (2016). CFTR is a tumor suppressor gene in murine and human intestinal cancer. Oncogene35 (32), 4179–4187. 10.1038/onc.2015.483

  • CrossRef
  • Google Scholar

• 160

  TirouvanziamR.ConradC. K.BottiglieriT.HerzenbergL. A.MossR. B.HerzenbergL. A. (2006). High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Proc. Natl. Acad. Sci.103 (12), 4628–4633. 10.1073/pnas.0511304103

  • CrossRef
  • Google Scholar

• 161

  ToscoA.De GregorioF.EspositoS.De StefanoD.SanaI.FerrariE.et al (2016). A novel treatment of cystic fibrosis acting on-target: cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTR. Cell Death Differ23 (8), 1380–1393. 10.1038/cdd.2016.22

  • CrossRef
  • Google Scholar

• 162

  TsuiL.-C. (1995). The cystic fibrosis transmembrane conductance regulator gene. Am. J. Respir. Crit. Care Med.151 (3 Pt 2), S47–S53. 10.1164/ajrccm/151.3_pt_2.s47

  • CrossRef
  • Google Scholar

• 163

  TuZ.ChenQ.ZhangJ. T.JiangX.XiaY.ChanH. C. (2016). CFTR is a potential marker for nasopharyngeal carcinoma prognosis and metastasis. Oncotarget7 (47), 76955–76965. 10.18632/oncotarget.12762

  • CrossRef
  • Google Scholar

• 164

  ValdiviesoA. G.ClauzureM.MarínM. C.TaminelliG. L.Massip CopizM. M.SánchezF.et al (2012). The mitochondrial complex I activity is reduced in cells with impaired cystic fibrosis transmembrane conductance regulator (CFTR) function. PLoS One7 (11), e48059. 10.1371/journal.pone.0048059

  • CrossRef
  • Google Scholar

• 165

  Van BiervlietS.DevosM.DelhayeT.Van BiervlietJ. P.RobberechtE.ChristopheA. (2008). Oral DHA supplementation in ΔF508 homozygous cystic fibrosis patients. Prostaglandins, Leukot. Essent. Fatty Acids78 (2), 109–115. 10.1016/j.plefa.2007.12.005

  • CrossRef
  • Google Scholar

• 166

  Van GoorF.HadidaS.GrootenhuisP. D. J.BurtonB.StackJ. H.StraleyK. S.et al (2011). Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc. Natl. Acad. Sci.108 (46), 18843–18848. 10.1073/pnas.1105787108

  • CrossRef
  • Google Scholar

• 167

  VellaiT. (2009). Autophagy genes and ageing. Cel Death Differ16 (1), 94–102. 10.1038/cdd.2008.126

  • CrossRef
  • Google Scholar

• 168

  VelsorL. W.KariyaC.KachadourianR.DayB. J. (2006). Mitochondrial oxidative stress in the lungs of cystic fibrosis transmembrane conductance regulator protein mutant mice. Am. J. Respir. Cel Mol Biol35 (5), 579–586. 10.1165/rcmb.2005-0473oc

  • CrossRef
  • Google Scholar

• 169

  VelsorL. W.van HeeckerenA.DayB. J. (2001). Antioxidant imbalance in the lungs of cystic fibrosis transmembrane conductance regulator protein mutant mice. Am. J. Physiology-Lung Cell Mol. Physiol.281 (1), L31–L38. 10.1152/ajplung.2001.281.1.l31

  • CrossRef
  • Google Scholar

• 170

  VenckenS.FogedC.RamseyJ. M.SweeneyL.CryanS. A.MacLoughlinR. J.et al (2019). Nebulised lipid-polymer hybrid nanoparticles for the delivery of a therapeutic anti-inflammatory microRNA to bronchial epithelial cells. ERJ Open Res.5 (2). 10.1183/23120541.00161-2018

  • CrossRef
  • Google Scholar

• 171

  VillellaV. R.EspositoS.BrusciaE. M.VicinanzaM.CenciS.GuidoS.et al (2013). Disease-relevant proteostasis regulation of cystic fibrosis transmembrane conductance regulator. Cel Death Differ20 (8), 1101–1115. 10.1038/cdd.2013.46

  • CrossRef
  • Google Scholar

• 172

  WainwrightC. E.ElbornJ. S.RamseyB. W.MarigowdaG.HuangX.CipolliM.et al (2015). Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N. Engl. J. Med.373 (3), 220–231. 10.1056/nejmoa1409547

  • CrossRef
  • Google Scholar

• 173

  ZelvyteI.DominaitieneR.CrisbyM.JanciauskieneS. (2002). Modulation of inflammatory mediators and pparγand nfκb expression by pravastatin in response to lipoproteins in human monocytes in vitro. Pharmacol. Res.45 (2), 147–154. 10.1006/phrs.2001.0922

  • CrossRef
  • Google Scholar

• 174

  ZingarelliB.SheehanM.HakeP. W.O’ConnorM.DenenbergA.CookJ. A. (2003). Peroxisome proliferator activator receptor-γ ligands, 15-deoxy-d12,14-prostaglandin J2 and ciglitazone, reduce systemic inflammation in polymicrobial sepsis by modulation of signal transduction pathways. J. Immunol.171 (12), 6827–6837. 10.4049/jimmunol.171.12.6827

  • CrossRef
  • Google Scholar